Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/27/2025 | $3.50 | Overweight | Barclays |
| 5/14/2025 | $4.00 | Buy | H.C. Wainwright |
| 12/20/2024 | $12.00 → $15.00 | Buy | H.C. Wainwright |
| 12/11/2023 | $6.00 | Buy | H.C. Wainwright |
| 8/14/2023 | $2.75 → $3.50 | Underweight → Neutral | Piper Sandler |
| 6/22/2023 | $6.00 | Overweight | Cantor Fitzgerald |
| 5/16/2022 | $10.00 → $4.00 | Overweight → Underweight | Piper Sandler |
| 10/29/2021 | $17.00 | Outperform | Cowen & Co. |
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access - - Conference call today at 8:00 am ET - DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a c
- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. - - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarter and Year End Financial Results and Corporate UpdateDateMarch 27, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50
H.C. Wainwright resumed coverage of Humacyte with a rating of Buy and set a new price target of $4.00
H.C. Wainwright reiterated coverage of Humacyte with a rating of Buy and set a new price target of $15.00 from $12.00 previously
10-K - Humacyte, Inc. (0001818382) (Filer)
SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)
8-K - Humacyte, Inc. (0001818382) (Filer)
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarter and Year End Financial Results and Corporate UpdateDateMarch 27, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercia
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2025 Financial Results and Corporate UpdateDate:November 12, 2025Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13756236 (Conference ID)Call me™ Feature
- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. - - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan
BioAesthetics Corporation announced today the appointment of Juliana Blum, PhD as its new Chief Executive Officer, effective August 12, 2024. Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc. said, "This is an important milestone for BioAesthetics. During the development of every successful biotech company, there comes a time when the founding CEO transitions to a different role and a new CEO with different skill sets is needed for product advancement and commercialization. Dr. Blum's experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics." Dr. Blum joins BioAesthetics following her 20 years spent as Co-founder
DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors. "Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board," said Kathleen Sebelius, Chair of Humacyte's board of directors. "Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV). We al
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)